| [1] |
Zhu AX, Hong TS, Hezel AF, et al. Current management of gallbladder carcinoma[J]. Oncologist, 2010, 15(2):168-181.
|
| [2] |
Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome[J]. Clin Epidemiol, 2014(6):99-109.
|
| [3] |
刘静明，倪慕云，樊菊芬，等．青篙素（Arteannuin）的结构和反应[J]．化学学报，1979, 37(2):129-143.
|
| [4] |
Lu JJ, Chen SM, Zhang XW, et al. The anti-cancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells[J]. Invest New Drugs, 2011, 29(6):1276-1283.
|
| [5 |
Chen T, Li M, Zhang R, et al. Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy[J]. J Cell Mol Med, 2009, 13(7):1358-1370.
|
| [6] |
Wang J, Zhang B, Guo Y, et al. Artemisinin inhibits tumor lymphangiogenesis by suppression of vascular endothelial growth factor C[J]. Pharmacology, 2008, 82(2):148-155.
|
| [7] |
Sundar SN, Marconett CN, Doan VB, et al. Artemisinin selectively decreases functional levels of estrogen receptor-alpha and ablates estrogen-induced proliferation in human breast cancer cells[J]. Carcinogenesis, 2008, 29(12):2252-2258.
|
| [8] |
Weifeng T, Feng S, Xiangji L, et al. Artemisinin inhibits in vitro and in vivo invasion and metastasis of human hepatocellular carcinoma cells[J]. Phytomedicine, 2011, 18(2/3):158-162.
|
| [9] |
Morrissey C, Gallis B, Solazzi JW, et al. Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells[J]. Anticancer Drugs, 2010, 21(4):423-432.
|
| [10] |
Jia J, Qin Y, Zhang L, et al. Artemisinin inhibits gallbladder cancer cell lines through triggering cell cycle arrest and apoptosis[J]. Mol Med Rep, 2016, 13(5):4461-4468.
|
| [11] |
Bhaw-Luximon A, Jhurry D. Artemisinin and its derivatives in cancer therapy: status of progress, mechanism of action, and future perspectives[J]. Cancer Chemother Pharmacol, 2017, 79(3):451-466.
|
| [12] |
Chaturvedi D, Goswami A, Saikia PP, et al. Artemisinin and its derivatives: a novel class of anti-malarial and anti-cancer agents[J]. Chem Soc Rev, 2010, 39(2):435-454.
|
| [13] |
Tong Y, Liu Y, Zheng H, et al. Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling[J]. Oncotarget, 2016, 7(21):31413-31428.
|
| [14] |
Gong XM, Zhang Q, Torossian A, et al. Selective radiosensitization of human cervical cancer cells and normal cells by artemisinin through the abrogation of radiation-induced G2 block[J]. Int J Gynecol Cancer, 2012, 22(5):718-724.
|
| [15] |
Liu Y, Wang W, Xu J, et al. Dihydroartemisinin inhibits tumor growth of human osteosarcoma cells by suppressing Wnt/β-catenin signaling[J]. Oncol Rep, 2013, 30(4):1723-1730.
|
| [16] |
Fröhlich T, Çapcı Karagöz A, Reiter C, et al. Artemisinin-derived dimers: potent antimalarial and anticancer agents[J]. J Med Chem, 2016, 59(16):7360-7388.
|
| [17] |
Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition[J]. Nat Rev Mol Cell Biol, 2014, 15(3):178-196.
|
| [18] |
Davis FM, Stewart TA, Thompson EW, et al. Targeting EMT in cancer: opportunities for pharmacological intervention[J]. Trends Pharmacol Sci, 2014, 35(9):479-488.
|
| [19] |
Lee DG, Lee SH, Kim JS, et al. Loss of NDRG2 promotes epithelial-mesenchymal transition of gallbladder carcinoma cells through MMP-19-mediated Slug expression[J]. J Hepatol, 2015, 63(6):1429-1439.
|
| [20] |
Lian S, Shao Y, Liu H, et al. PDK1 induces JunB, EMT, cell migration and invasion in human gallbladder cancer[J]. Oncotarget, 2015, 6(30):29076-29086.
|
| [21] |
Bolós V, Peinado H, Pérez-Moreno MA, et al. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors[J]. J Cell Sci, 2003, 116(Pt 3):499-511.
|
| [22] |
Zheng H, Takahashi H, Murai Y, et al. Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma[J]. Anticancer Res, 2006, 26(5A):3579-3583.
|